Trinity Biotech appoints Paul Tivnan as non-executive director

Trinity Biotech plc (NASDAQ: TRIB) announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director, according to a company press release.

Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance across infrastructure, energy, shipping, and cleantech sectors. He currently serves as Chief Financial Officer of Deriva Energy LLC, described as one of the largest independent renewable power producers in the United States and a Brookfield portfolio company.

His previous roles include CFO of Brookfield Renewable Ireland and CFO of Ardmore Shipping Corporation, where he led the company's IPO on the New York Stock Exchange in 2013. Tivnan has also served as a Director of Element 1 Corp, a developer of hydrogen technologies.

"We are delighted to welcome Paul to the Board," said John Gillard, President and Chief Executive Officer of Trinity Biotech. "His extensive experience in capital markets and operational leadership across large scale global sectors will be invaluable to our company as we continue to execute our transformation strategy and pursue growth opportunities in diagnostics and wearable health technologies."

Tivnan is a Certified International Director from INSEAD Business School and has completed executive leadership and corporate governance programs at INSEAD and London Business School. He previously worked at Ernst & Young in Financial Services Advisory, specializing in international tax and corporate structuring.

He holds a B.A. degree in Accounting and Finance and a Master of Business Studies degree from Dublin City University. Tivnan is a Fellow of the Institute of Chartered Accountants of Ireland, a Chartered Tax Advisor, and a member of the Institute of Chartered Shipbrokers.

Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors.

You May Also Be Interested In

• Bulldog Investors urges no vote on XFLT sub-advisor proposal
• Trump: 40-60% of chip manufacturing will be in the U.S. - CNBC Interview
• New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring